Core Viewpoint - InnoCare Pharma (03696) has seen its stock price rise over 5%, reaching a new high of HKD 40.5, following the announcement of a multi-year R&D collaboration with Servier worth USD 888 million [1] Group 1: Company Developments - InnoCare Pharma announced a partnership with Servier to utilize its AI platform Pharma.AI, focusing on challenging targets in the oncology field to identify and develop new therapeutic drugs [1] - The agreement allows InnoCare to receive up to USD 32 million in upfront payments and milestone payments for recent R&D achievements [1] - InnoCare will lead the discovery and development of potential drug candidates using its AI technology, while Servier will co-fund the R&D and lead subsequent clinical validation and commercialization [1] Group 2: Industry Insights - According to recent research from Xiangcai Securities, AI technology has found suitable applications in various stages of the pharmaceutical process, demonstrating significant potential [1] - The report highlights that in the increasingly competitive landscape of innovative drug development, the underlying innovations brought by AI technology in drug R&D showcase immense value [1]
港股异动 | 英矽智能(03696)再涨超5%创新高 近日宣布与施维雅达成8.88亿美元合作